先前患有恶性肿瘤的真性红细胞增多症和原发性血小板增多症患者的预后并无显著恶化。
Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome.
机构信息
Department of Hematology and Oncology, The University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA.
出版信息
Leuk Res. 2013 Nov;37(11):1472-6. doi: 10.1016/j.leukres.2013.08.002. Epub 2013 Aug 14.
Abstract
The clinical relevance of prior malignancy (PM) in patients with essential thrombocythemia (ET) and polycythemia vera (PV) is largely unknown. We retrospectively evaluated 437 patients (ET, n=263; PV, n=174) treated at MD Anderson between 1960 and 2010. Forty-four patients had PM (ET, 10%; PV, 11%), with median time to diagnosis of 66 months. PM was not associated with abnormal cytogenetics, JAK2-mutation frequency, blood-cell counts or progression to acute leukemia or myelofibrosis. In multivariate analysis, only older age and high LDH levels were associated with worse OS. In conclusion, PM does not predict worse outcomes for patients with ET and PV.
摘要
在原发性骨髓纤维化（PM）患者中，先前恶性肿瘤（PM）的临床相关性在很大程度上尚不清楚。我们回顾性评估了 1960 年至 2010 年间在 MD 安德森治疗的 437 名患者（ET，n=263；PV，n=174）。44 名患者患有 PM（ET，10%；PV，11%），中位诊断时间为 66 个月。PM 与异常细胞遗传学、JAK2 基因突变频率、血细胞计数或进展为急性白血病或骨髓纤维化无关。多变量分析显示，仅年龄较大和高乳酸脱氢酶水平与较差的总生存期相关。总之，PM 并不能预测 ET 和 PV 患者的预后更差。
相似文献
1
Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome.先前患有恶性肿瘤的真性红细胞增多症和原发性血小板增多症患者的预后并无显著恶化。
Leuk Res. 2013 Nov;37(11):1472-6. doi: 10.1016/j.leukres.2013.08.002. Epub 2013 Aug 14.
2
Clinical predictors of outcome in MPN.骨髓增殖性肿瘤（MPN）结局的临床预测因素。
Hematol Oncol Clin North Am. 2012 Oct;26(5):1101-16. doi: 10.1016/j.hoc.2012.07.009. Epub 2012 Aug 28.
3
Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.动态国际预后评分系统与原发性骨髓纤维化继发于 PV 和 ET 预后模型在异基因造血干细胞移植后对真性红细胞增多症和原发性血小板增多症骨髓纤维化结局预测的比较。
Biol Blood Marrow Transplant. 2019 Jun;25(6):e204-e208. doi: 10.1016/j.bbmt.2019.03.024. Epub 2019 Mar 28.
4
Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.真性红细胞增多症和原发性血小板增多症中的血栓出血事件、疾病进展及生存情况：日本宫崎县的一项回顾性调查
Int J Hematol. 2018 Jun;107(6):681-688. doi: 10.1007/s12185-018-2428-0. Epub 2018 Feb 27.
5
Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.真性红细胞增多症和原发性血小板增多症在日本的临床特征：日本老年白血病和淋巴瘤研究组全国性调查的回顾性分析
Int J Hematol. 2006 Jun;83(5):443-9. doi: 10.1532/IJH97.06009.
6
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.原发性骨髓纤维化和真性红细胞增多症后/或原发性血小板增多症后骨髓纤维化患者接受芦可替尼治疗的临床表现、结局和预后模型的差异。一项大型多中心研究中 MYSEC-PM 的新视角。
Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.
7
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.一个临床-分子预后模型，用于预测真性红细胞增多症后和特发性血小板增多症后骨髓纤维化患者的生存情况。
Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.
8
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.真性红细胞增多症和原发性血小板增多症：2019 年诊断、风险分层和治疗更新。
Am J Hematol. 2019 Jan;94(1):133-143. doi: 10.1002/ajh.25303. Epub 2018 Nov 9.
9
Contemporary approach to essential thrombocythemia and polycythemia vera.原发性血小板增多症和真性红细胞增多症的现代治疗方法
Curr Opin Hematol. 2016 Mar;23(2):150-60. doi: 10.1097/MOH.0000000000000216.
10
Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.同种异体造血细胞移植治疗晚期原发性骨髓纤维化和原发性血小板增多症。
Biol Blood Marrow Transplant. 2012 Sep;18(9):1446-54. doi: 10.1016/j.bbmt.2012.03.009. Epub 2012 Mar 24.
引用本文的文献
1
Retrospective analysis of the clinical features of 172 patients with -negative chronic myeloproliferative neoplasms.172例阴性慢性骨髓增殖性肿瘤患者临床特征的回顾性分析。
Mol Cytogenet. 2020 Feb 17;13:8. doi: 10.1186/s13039-020-0471-z. eCollection 2020.
2
Epidemiology of MPN: what do we know?骨髓增殖性肿瘤的流行病学：我们了解什么？
Curr Hematol Malig Rep. 2014 Dec;9(4):340-9. doi: 10.1007/s11899-014-0228-z.
本文引用的文献
1
Analysis on 71 patients with polycythemia vera.71例真性红细胞增多症患者的分析。
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20(3):667-70.
2
Cancer treatment and survivorship statistics, 2012.癌症治疗与生存统计，2012 年。
CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41. doi: 10.3322/caac.21149. Epub 2012 Jun 14.
3
Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.原发性血小板增多症（ET）中的第二原发性恶性肿瘤：来自单一机构的331例长期随访患者的回顾性分析
Hematology. 2008 Aug;13(4):195-202. doi: 10.1179/102453308X316022.
4
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.真性红细胞增多症和特发性红细胞增多症中的JAK2外显子12突变
N Engl J Med. 2007 Feb 1;356(5):459-68. doi: 10.1056/NEJMoa065202.
5
Increased serum lactate dehydrogenase isoenzymes in Ph-negative chronic myeloproliferative diseases: a metabolic adaptation?Ph阴性慢性骨髓增殖性疾病中血清乳酸脱氢酶同工酶升高：一种代谢适应？
Hematology. 2006 Aug;11(4):239-44. doi: 10.1080/10245330600774835.
6
7
Second malignancies in patients with essential thrombocythaemia.原发性血小板增多症患者的第二原发性恶性肿瘤。
Br J Haematol. 2002 Mar;116(4):923-4. doi: 10.1111/j.1365-2141.2002.3346_1.x.
8
Essential thrombocythemia in children.
J Pediatr Hematol Oncol. 1999 Sep-Oct;21(5):356-63. doi: 10.1097/00043426-199909000-00005.
9
Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).以哌泊溴烷单药治疗真性红细胞增多症：在一组观察20年（1971 - 1991年）的患者中继发性白血病发生率低。
Leukemia. 1998 Jun;12(6):869-74. doi: 10.1038/sj.leu.2401045.
10
Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.自发性红系集落形成作为布加综合征或门静脉血栓形成患者潜在骨髓增殖性疾病的线索。
Semin Thromb Hemost. 1997;23(5):411-8. doi: 10.1055/s-2007-996117.
Zotero 插件